Further analysis revealed that immune checkpoint genes CD47, PVR, SIRPA, and VTCN1 were found to be elevated in the high-risk cohort, indicating their role in suppressing anti-tumor immunity (Figure 5G). This evidence concerns the gene VTCN1 and neoplasm.